Real World Evidence Solutions Market Growth, Trends, Industry Statistics 2022-2030

The global Real World Evidence Solutions market size is expected to be worth around US$ 70.4 billion by 2030, according to a new report by Vision Research Reports.

The global Real World Evidence Solutions market size was valued at US$ 38.2 billion in 2020 and is anticipated to grow at a CAGR of 8.6% during forecast period 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39021

Report Coverage

Report Scope Details
Market Size US$ 70.4 billion by 2030
Growth Rate CAGR of 8.6% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Component, Application, End user
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned IQVIA; IBM; PPD, Inc.; Parexel International Corp.; PerkinElmer, Inc.; Icon Plc; Oracle; Syneos Health; Cegedim Health Data; Medpace

Growth Factors

The key factors driving the real world evidence solutions (RWE) market growth include the favorable government regulations and shift from volume to value-based care. Furthermore, the increasing prevalence of chronic disorders is anticipated to positively influence market growth.

Support from regulatory bodies for using real world evidence (RWE) solutions and an increase in R&D spending are anticipated to boost the market growth. Furthermore, the shift from volume to value-based care is expected to fuel market growth.

During the pandemic, companies in the market diverted their focus towards providing solutions for curbing the spread of COVID-19. For instance, IBM collaborated with Salesforce for building digital health passes, which incorporated data, such as vaccine status, temperature checks, and COVID-19 test results for helping organizations to reopen safely.

By Component Analysis

The services segment accounted for the maximum revenue share of more than 57% in 2020. The market growth is attributed to the high adoption of real-world services by pharmaceutical & biotechnology companies as well as healthcare providers.

The data sets segment consists of clinical settings data, claims data, pharmacy data, and patient-powered data. The segment is anticipated to witness growth owing to arise in the volume of data generated in healthcare facilities and growing attention for additional insights on epidemiology.

By Application Analysis

The drug development and approvals segment accounted for the highest revenue share of more than 29.5% in 2020. Real-world evidence solutions services allow pharmaceutical companies and healthcare providers as well as payers for efficient management of operations and accelerate the process of drug development and its approval.

The reimbursement/coverage and regulatory decision-making segment is expected to grow at the fastest CAGR of more than 8% from 2021 to 2030 owing to the rising focus towards clinical value evidence for making decisions to provide coverage and the rising therapy costs.

By End-user Analysis

The pharmaceutical & medical device companies segment accounted for the maximum revenue share of around 33.9% in 2020. The segment growth is attributed to the rising importance of RWE studies in the drug approval process, assessing drug performance in real-world settings, and preventing drug recalls.

The healthcare payers segment is expected to grow at the fastest growth rate of more than 8.5% over the forecast period owing to the increasing awareness among the payers regarding the importance of medical device/drug safety & their adverse effects and favorable reimbursement scenario, especially in developed countries.

By Regional Analysis

North America accounted for the largest revenue share of 44.4% in 2020. The large share of the region is credited to the presence of key players in the U.S. Rising number of RWE service providers and favorable government regulations in the region are expected to drive the market further.

Asia Pacific is expected to be the fastest-growing regional market during the forecast years owing to the rising government initiatives for the adoption of RWE studies and the presence of many Contract Research Organizations(CROs) and manufacturing companies in countries, such as China and India.

Key Players

  • IQVIA
  • IBM
  • PPD, Inc.
  • Parexel International Corp.
  • PerkinElmer, Inc.
  • Icon Plc
  • Oracle
  • Syneos Health
  • Cegedim Health Data
  • Medpace

Market Segmentation

  • By Component
    • Services
    • Data Sets
      • Clinical Settings Data
      • Claims Data
      • Pharmacy Data
      • Patient-Powered Data
  • By Application
    • Drug Development & Approvals
    • Medical Device Development & Approvals
    • Reimbursement/Coverage & Regulatory Decision Making
    • Post Market Safety & Adverse Events Monitoring
  • By End-user
    • Pharmaceutical & Medical Device Companies
    • Healthcare Payers
    • Healthcare Providers
    • Others
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • MEA
      • South Africa
      • Saudi Arabia
      • Israel

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39021

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Real World Evidence Solutions Market, By Component

7.1.  Real World Evidence Solutions Market, by Component, 2021-2030

7.1.1.    Services

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Data Sets

7.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Real World Evidence Solutions Market, By Application

8.1.  Real World Evidence Solutions Market, by Application, 2021-2030

8.1.1.    Drug Development & Approvals

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Medical Device Development & Approvals

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Reimbursement/Coverage & Regulatory Decision Making

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Post Market Safety & Adverse Events Monitoring

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Real World Evidence Solutions Market, By End User

9.1.  Real World Evidence Solutions Market, by End User, 2021-2030

9.1.1.    Pharmaceutical & Medical Device Companies

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Healthcare Payers

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Healthcare Providers

9.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Real World Evidence Solutions Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Component (2017-2030)

10.1.2.  Market Revenue and Forecast, by Application (2017-2030)

10.1.3.  Market Revenue and Forecast, by End User (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Component (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Component (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Component (2017-2030)

10.2.2.  Market Revenue and Forecast, by Application (2017-2030)

10.2.3.  Market Revenue and Forecast, by End User (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Component (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Component (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Component (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Component (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Component (2017-2030)

10.3.2.  Market Revenue and Forecast, by Application (2017-2030)

10.3.3.  Market Revenue and Forecast, by End User (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Component (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Component (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Component (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Component (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Component (2017-2030)

10.4.2.  Market Revenue and Forecast, by Application (2017-2030)

10.4.3.  Market Revenue and Forecast, by End User (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Component (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Component (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Component (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Component (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Component (2017-2030)

10.5.2.  Market Revenue and Forecast, by Application (2017-2030)

10.5.3.  Market Revenue and Forecast, by End User (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Component (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Component (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by End User (2017-2030)

Chapter 11.  Company Profiles

11.1.              IQVIA

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              IBM

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              PPD, Inc.

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Parexel International Corp.

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              PerkinElmer, Inc.

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Icon Plc

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Oracle

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Syneos Health

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Cegedim Health Data

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Medpace

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39021

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com